Clostridium tertium was isolated from two immunocompromised patients with septicemia, fever, and gastrointestinal symptoms. The strains were resistant to ceftazidime, cefepime, and clindamycin; intermediately resistant to penicillin; and susceptible to metronidazole, quinolones, and vancomycin. CASE REPORTS Case 1. A 65-year-old male was diagnosed with acute myeloid leukemia and treated with chemotherapy. During neutropenia, he became febrile and developed abdominal pain and watery diarrhea after the institution of ceftazidime and amikacin. Six sets of blood cultures revealed Clostridium tertium. Vancomycin was administered with good therapeutic response.
Blood was inoculated in BacT/Alert anaerobic and FAN aerobic bottles and incubated at 37°C in the BacT/Alert3D instrument (Organon Teknika, Turnhout, Belgium). Gram staining revealed gram-negative rods with a "squarish" morphology and intracellular gram-positive granules. Subculture on blood agar (Becton Dickinson, Erembodegem, Belgium) revealed small colonies after 24 h at 37°C in a 5% CO 2 -enriched atmosphere. More luxuriant growth of gray, translucent colonies with an irregular, nonspreading edge could be seen on the plates incubated anaerobically at 37°C in a jar by using GasPak Plus (Becton Dickinson). Terminal oval spores could be demonstrated in organisms incubated anaerobically. The catalase test was negative. Both strains fermented carbohydrates, but were nonproteolytic. No lipase or lecithinase activity was present. The first strain reduced nitrate, while the second did not. The Api20A (bio-Mérieux, Marcy-l'Etoile, France) strip produced a profile number, 4 774 602 3, giving an identification as C. tertium with a probability of 98.9% for the first strain and a profile number, 4 774 612 3, with a probability of 99.9% for the second. MICs (Table 1) were determined by using the E test (AB Biodisk, Solna, Sweden) on brucella blood agar supplemented with hemin and vitamin K 1 (Becton Dickinson, Erembodegem, Belgium) under anaerobic conditions for 48 h (6, 12) . Quality control was performed by the Stokes method with Bacteroides fragilis ATCC 25285. No ␤-lactamase production was detected.
The identification as C. tertium was confirmed for both strains by means of amplified ribosomal DNA restriction analysis (11) . The AluI pattern consisted of fragments of approximately 60, 110, 190, 210, 230, and 610 bp, and the CfoI pattern consisted of fragments of approximately 210, 410, and 840 bp. The patterns were completely identical for reference strain NIH 4522 and both clinical strains. Sequence determination of the amplified 16S rRNA gene (first 800 bp) of the first clinical strain revealed 98% identity with C. chauvoei (GenBank U51843) and 97% identity with C. septicum (GenBank U59278) as the closest matches. However, the database contained no C. tertium sequences. Therefore, the type strain of C. tertium (ATCC 14573) was sequenced (GenBank AJ245413, Thierry De Baere). Comparison of the first 800 bp of 16S rRNA of the first clinical strain (GenBank AJ132605, Mario Vaneechoutte) with that of the type strain revealed 100% sequence identity.
C. tertium has been isolated from soil (1), the oral cavity (4), feces of healthy neonates and infants (1), appendices and feces of healthy adults (1), and 5 to 26% of fecal specimens of patients (8) . This species has been isolated in relation to a brain abscess (1), meningitis (5), neutropenic enterocolitis (2), soft tissue infections (1), and war wounds (1) . C. tertium is usually regarded as nonpathogenic, and no toxin production has been described (1) . Clostridium species account for 0.5 to 2% of all clinically significant bacteria in blood cultures, with C. perfringens as the most common isolate (7). The significance of C. tertium in blood cultures is unclear, particularly in polymicrobial cultures (3). Our patients presented with fever and gastrointestinal symptoms with C. tertium as the only isolate. Therefore, we considered both isolates to be clinically significant. In previous reports, C. tertium septicemia in neutropenic patients has been associated with abdominal discomfort, diarrhea, colonic bleeding, or perianal cellulitis (8, 9) . The intestinal mucosa is a rapidly proliferating epithelium which can be damaged by treatment with antineoplastic drugs. This mucosal damage is the most likely portal of entry for C. tertium. The chance of fecal carriage of C. tertium in the setting of neutropenia may be related to selection by previously administered antimicrobial agents (2, 3, (8) (9) (10) . This could explain the emergence of C. tertium as a pathogen in neutropenic patients, because this organism is resistant to standard empirical antibiotic regimens, such as ceftazidime (2a), and was shown here to be resistant to expanded-spectrum cephalosporins with enhanced activity against gram-positive organisms, such as cefepime.
C. tertium is a gram-positive organism that is easily decolorized in gram-stained smears and can be mistaken for a gramnegative organism. However, C. tertium does not grow on selective media for gram-negative organisms. The aerotolerance of C. tertium can result in the misidentification of this organism as Bacillus spp. or Lactobacillus spp. A negative catalase test is an easy tool to differentiate C. tertium from Bacillus spp., which are catalase positive. C. tertium will only form spores under anaerobic conditions, in contrast to Bacillus spp., which will sporulate aerobically. Lactobacilli are catalase negative, but do not form spores and grow on a tomato juice agar. Other aerotolerant Clostridium species are C. carnis and C. histolyticum (Table 2) . Although penicillin and clindamycin show excellent activity against most of the clostridial species, resistance can occur for C. tertium (1, (8) (9) (10) . In general, metronidazole (3, (8) (9) (10) , fluoroquinolones (8) , and imipenem (8, 10) are active against C. tertium, while aminoglycosides (4), ceftazidime, and other expanded-spectrum ␤-lactam drugs are not (4, 8, 9) . Although cefepime is an expanded-spectrum cephalosporin with enhanced activity against gram-positive organisms, both strains reported here were resistant to cefepime. Vancomycin appears to be efficacious (8, 9) .
In conclusion, C. tertium is not common and is not very virulent, but appears to be an emerging pathogen in neutropenic patients. The recognition of C. tertium is hampered by its aerotolerance and variable gram-staining properties, and this organism may be refractory to standard antimicrobial agents such as ceftazidime and cefepime. 
